Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy,
safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in
adult participants with paraxysmal noturnal hemoglobinuria (PNH) in China.